Benzimidazole nucleosides have been shown to be potent inhibitors of human cytomegalovirus (HCMV) replication in vitro. As part of the exploration of structure-activity relationships within this series, we synthesized the 2-isopropylamino derivative (3322W93) of 1H-␤-D-ribofuranoside-2-bromo-5,6-dichlorobenzimidazole (BDCRB) and the biologically unnatural L-sugars corresponding to both compounds. One of the L derivatives, 1H-␤-L-ribofuranoside-2-isopropylamino-5,6-dichlorobenzimidazole (1263W94), showed significant antiviral potency in vitro against both laboratory HCMV strains and clinical HCMV isolates, including those resistant to ganciclovir (GCV), foscarnet, and BDCRB. 1263W94 inhibited viral replication in a dose-dependent manner, with a mean 50% inhibitory concentration (IC 50 ) of 0.12 ؎ 0.01 M compared to a mean IC 50 for GCV of 0.53 ؎ 0.04 M, as measured by a multicycle DNA hybridization assay. In a single replication cycle, 1263W94 treatment reduced viral DNA synthesis, as well as overall virus yield. HCMV mutants resistant to 1263W94 were isolated, establishing that the target of 1263W94 was a viral gene product. The resistance mutation was mapped to the UL97 open reading frame. The pUL97 protein kinase was strongly inhibited by 1263W94, with 50% inhibition occurring at 3 nM. Although HCMV DNA synthesis was inhibited by 1263W94, the inhibition was not mediated by the inhibition of viral DNA polymerase. The parent benzimidazole D-riboside BDCRB inhibits viral DNA maturation and processing, whereas 1263W94 does not. The mechanism of the antiviral effect of L-riboside 1263W94 is thus distinct from those of GCV and of BDCRB. In summary, 1263W94 inhibits viral replication by a novel mechanism that is not yet completely understood.Human cytomegalovirus (HCMV) is a herpesvirus that causes a benign infection in an estimated 40 to 100% of populations in the United States (reviewed by Sia and Patel [23]). In most cases, HCMV infection is not associated with disease; however, in patients with an immature or compromised immune system, HCMV infection can be a serious or even lifethreatening disease. Four drugs-ganciclovir (GCV), its prodrug valganciclovir, cidofovir, and foscarnet-are currently used for the treatment of systemic HCMV infection; however, there are a number of disadvantages associated with each of these therapies. Cidofovir and foscarnet are available only as intravenous formulations, whereas GCV is given intravenously for initial treatment of systemic disease. With all anti-HCMV drugs currently available, there can be serious side effects associated with prolonged treatment. In addition, the drugs have similar mechanisms of action, all ultimately targeting the HCMV polymerase; therefore, selection of crossresistant HCMV mutants can occur. Thus, there is a need for other therapeutic agents that are safe, potent, and orally bioavailable, with a novel mechanism of action.As part of an ongoing program to develop novel anti-HCMV compounds that could potentially yield new therapeutic agents for treatmen...

No abstract

The crystal structure of an inhibitory complex formed between Escherichia coli cytidine deaminase and the transition-state analog 3,4-dihydrouridine indicates the presence of a short H-bond between Glu-104 and the inhibitor. To test the possibility that analogous H-bonds might play a significant role in stabilizing the hydrated substrate in the transition state for deamination, we replaced Glu-104 by alanine. Compared with the wild-type enzyme, the mutant enzyme's affinities for substrate cytidine and product uridine were found to have increased, whereas kcat for deamination of cytidine had been reduced by 8 orders of magnitude. By its presence, the carboxymethyl group of Glu-104 appears to minimize the activation barrier for deamination, not only by stabilizing the altered substrate in the transition state but also by destabilizing the enzyme-substrate and enzyme-product complexes. In the presence of added formate ion, but not in the presence of bulkier carboxylic acids, the low catalytic activity of the mutant enzyme was enhanced substantially.

Cytidine deaminase from Escherichia coli contains 1 mol of tightly bound zinc per enzyme subunit (Yang, C., Carlow, D., Wolfenden, R., & Short, S.A. (1992) Biochemistry 31, 4168-4174). When the metal liganding residues Cys-129 and Cys-132 were replaced by Ala, and His-102 was replaced by Ala, Asn, or Gln, deaminase activities of cell extracts containing these mutant enzymes were decreased by several orders of magnitude relative to that of the wild-type enzyme. After purification, each mutant protein was found to contain less than 0.2 mol of zinc per enzyme subunit, except mutant H102Q, which contained 1 mol of zinc per subunit. The activity of each mutant enzyme increased in the presence of added zinc but never attained wild-type activity. Mutant H102N was unique in that this protein could be purified as a stable apoenzyme, activated by added zinc, and then inhibited by EDTA. This mutant enzyme bound zinc with an apparent Kd value of 6.0 x 10(-10) M and regained maximal activity in the presence of 1 mol of zinc per subunit. Affinities of the mutant cytidine deaminases for the transition-state analogue, 5-fluoropyrimidin-2-one ribonucleoside (3,4) hydrate, were found to decrease in rough proportion to kcat/Km over a range spanning several orders of magnitude. This variation in catalytic efficiency arose mainly from effects on kcat, indicating the involvement of zinc coordination in the catalytic process rather than in substrate binding.

Modification by covalent attachment of polyethylene glycol (PEG) can reduce the immunogenicity and prolong the circulating life of proteins, but the utility of this approach for any protein is restricted by the number and distribution of PEG attachment sites (e.g., e-amino groups of lysine residues). We have developed a strategy for introducing additional sites for PEG attachment by using site-directed mutagenesis to selectively replace arginine with lysine codons and tested it with purine nucleoside phosphorylase (PNP) from Escherchia coli, an extremely stable but immunogenic enzyme, that could potentially be used to treat an inherited deficiency of PNP. A triple mutant, RK3, possessing three Arg --Lys substitutions was constructed that increased the number of lysines per PNP subunit from 14 to 17, providing an additional 18 potential PEG attachment sites per hexameric enzyme molecule. The wild-type and RK3 enzymes had similar catalytic activity, antigenicity, and immunogenicity. After PEG modification, both enzymes retained catalytic activity, the plasma half-life of both enzymes in mice increased from 4 hr to 4 days, and the binding of both enzymes by antisera raised against each unmodified enzyme was markedly diminished.

No abstract

Abstract— The initial rate of uptake of [2,3‐3H]gamma‐aminobutyric acid by rat brain synaptosomes was studied under incubation conditions in which GABA metabolism was minimal. The presence of both sodium and potassium in the incubation medium was essential for sustained uptake. Uptake proceeded for a short period of time in the absence of potassium and then ceased. No uptake was observed when sodium chloride was completely replaced with sucrose or choline chloride. The sodium‐dependence curve for GABA uptake was markedly sigmoid. The sigmoid character of the curve was not attributable to a lag phase in uptake at low sodium concentrations. Calcium strongly stimulated the initial rate of uptake at low sodium concentrations but had little effect at sodium concentrations above 100 mm and was not able to support uptake in the absence of sodium. The sigmoid character of thesodium‐dependence curve was completely eliminated by 20 mm calcium ion. Magnesium and phosphate had little effect on the initial rate of GABA uptake.

The regulation of the expression of the Escherichia coli metF gene, which codes for 5,10-methylenetetrahydrofolate reductase (EC 1.1.99.15), has been investigated by using a simplified DNA-directed in vitro system that measures the formation of the first dipeptide (fMet-Ser) of the gene product. The synthesis of fMet-Ser directed by a plasmid containing the metF gene is specifically inhibited by metJ protein (repressor protein). S-Adenosylmethionine enhances the inhibition by the metJ protein of metF gene expression. The inhibition by the metJ protein is at the level of transcription and the results suggest that S-adenosylmethionine is functioning as an allosteric effector.